| 5.64 0.07 (1.26%) | 08-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.96 | 1-year : | 9.09 |
| Resists | First : | 6.81 | Second : | 7.78 |
| Pivot price | 6.07 |
|||
| Supports | First : | 5.23 | Second : | 4.35 |
| MAs | MA(5) : | 5.53 |
MA(20) : | 6.21 |
| MA(100) : | 4.94 |
MA(250) : | 4.92 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17.2 |
D(3) : | 11.4 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 7.78 | Low : | 2.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PSNL ] has closed above bottom band by 26.8%. Bollinger Bands are 38.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.86 - 5.88 | 5.88 - 5.9 |
| Low: | 5.5 - 5.52 | 5.52 - 5.55 |
| Close: | 5.6 - 5.63 | 5.63 - 5.68 |
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Tue, 05 Aug 2025
Personalis (PSNL): Navigating Near-Term Headwinds, Positioning for MRD Market Domination - AInvest
Tue, 05 Aug 2025
Personalis Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView
Tue, 05 Aug 2025
Personalis: Q2 Earnings Snapshot - San Antonio Express-News
Tue, 05 Aug 2025
Personalis Reports Mixed Q2: Clinical Tests Soar 59% While Revenue Falls 24% Amid Strategic Shift - Stock Titan
Sat, 02 Aug 2025
Personalis, Inc. (NASDAQ:PSNL) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing - simplywall.st
Fri, 18 Jul 2025
Personalis (NASDAQ:PSNL) Pulls Back 14% This Week, but Still Delivers Shareholders Splendid 284% Return Over 1 Year - 富途牛牛
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 88 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 31.4 (%) |
| Held by Institutions | 47 (%) |
| Shares Short | 6,850 (K) |
| Shares Short P.Month | 3,860 (K) |
| EPS | -1.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.34 |
| Profit Margin | -98.1 % |
| Operating Margin | -85.9 % |
| Return on Assets (ttm) | -17.9 % |
| Return on Equity (ttm) | -51.3 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 0.32 |
| Sales Per Share | 0.97 |
| EBITDA (p.s.) | -0.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -4.38 |
| PEG Ratio | 0 |
| Price to Book value | 2.4 |
| Price to Sales | 5.81 |
| Price to Cash Flow | -11.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|